Resultats de la cerca - Wechalekar, Ashutosh
- Mostrar 1 - 20 resultats de 55
- Anar a la pàgina següent
-
1
-
2
-
3
-
4
-
5
-
6
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of c... per Wechalekar, Ashutosh D., Gillmore, Julian D., Wassef, Nancy, Lachmann, Helen J., Whelan, Carol, Hawkins, Philip N.
Publicat 2011Text -
7
Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds per Wagner, T., Page, J., Burniston, M., Skillen, A., Ross, J. C., Manwani, R., McCool, D., Hawkins, P. N., Wechalekar, Ashutosh D.
Publicat 2018Text -
8
-
9
Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study per Banypersad, Sanjay M, Fontana, Marianna, Maestrini, Viviana, Sado, Daniel, White, Steven K, Treibel, Thomas A, Lachmann, Helen, Wechalekar, Ashutosh, Hawkins, Philip N, Moon, James
Publicat 2014Text -
10
Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain Amyloidosis per Gillmore, Julian D., Lachmann, Helen J., Rowczenio, Dorota, Gilbertson, Janet A., Zeng, Cai-Hong, Liu, Zhi-Hong, Li, Lei-Shi, Wechalekar, Ashutosh, Hawkins, Philip N.
Publicat 2009Text -
11
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis per Sharpley, Faye A., Manwani, Richa, Mahmood, Shameem, Sachchithanantham, Sajitha, Lachmann, Helen J., Gillmore, Julian D., Whelan, Carol J., Fontana, Marianna, Hawkins, Philip N., Wechalekar, Ashutosh D.
Publicat 2019Text -
12
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis per Sachchithanantham, Sajitha, Offer, Mark, Venner, Christopher, Mahmood, Shameem A., Foard, Darren, Rannigan, Lisa, Lane, Thirusha, Gillmore, Julian D., Lachmann, Helen J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Publicat 2015Text -
13
Deferred autologous stem cell transplantation in systemic AL amyloidosis per Manwani, Richa, Hegenbart, Ute, Mahmood, Shameem, Sachchithanantham, Sajitha, Kyriakou, Charalampia, Yong, Kwee, Popat, Rakesh, Rabin, Neil, Whelan, Carol, Dittrich, Tobias, Kimmich, Christoph, Hawkins, Philip, Schönland, Stefan, Wechalekar, Ashutosh
Publicat 2018Text -
14
Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria per Sharpley, Faye A., Fontana, Marianna, Martinez-Naharro, Ana, Manwani, Richa, Mahmood, Shameem, Sachchithanantham, Sajitha, Lachmann, Helen J., Gillmore, Julian D., Whelan, Carol J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Publicat 2020Text -
15
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic per Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria T., Blade, Joan, Dimopoulos, Meletios A.
Publicat 2020Text -
16
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis per Ravichandran, Sriram, Law, Steven, Mahmood, Shameem, Wisniowski, Brenden, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Publicat 2022Text -
17
Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis per Dungu, Jason, Whelan, Carol J, Gibbs, Simon D, Pinney, Jennifer H, Banypersad, Sanjay M, Venner, Christopher P, Lachmann, Helen J, Wechalekar, Ashutosh, Gillmore, Julian D, Hawkins, Philip N, Anderson, Lisa
Publicat 2012Text -
18
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis per Manwani, Richa, Foard, Darren, Mahmood, Shameem, Sachchithanantham, Sajitha, Lane, Thirusha, Quarta, Cristina, Youngstein, Taryn, Rezk, Tamer, Lachmann, Helen J, Gillmore, Julian D., Fontana, Marianna, Whelan, Carol, Hawkins, Philip N., Wechalekar, Ashutosh
Publicat 2018Text -
19
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib per Ravichandran, Sriram, Cohen, Oliver C., Law, Steven, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Sachchithanantham, Sajitha, Mahmood, Shameem, Hawkins, Philip N., Wechalekar, Ashutosh D.
Publicat 2021Text -
20
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis per Rezk, Tamer, Gilbertson, Janet A, Mangione, P Patrizia, Rowczenio, Dorota, Rendell, Nigel B, Canetti, Diana, Lachmann, Helen J, Wechalekar, Ashutosh D, Bass, Paul, Hawkins, Philip N, Bellotti, Vittorio, Taylor, Graham W, Gillmore, Julian D
Publicat 2019Text